Article Dans Une Revue Clinical and Translational Medicine Année : 2024

STING‐ATF3/type I interferon crosstalk: A potential target to improve anti‐tumour immunity in chemotherapy‐treated urothelial carcinoma

Anne Jarry
Yves Allory

Résumé

Upper Tract Urothelial Carcinomas (UTUC) are extremely aggressive and immunosuppressed tumors of the ureter or renal pelvis with a high relapse rate (>50%). Here, we assessed the mechanism of action of chemotherapy combinations (platinum salts and gemcitabine) in 2D and 3D UTUC cell cultures, including heterotypic spheroids. The tested combinations induced immunogenic cell death associated with the activation of DNA damage pathways and STING signaling, but not type I interferon (IFN-I). We identified the ATF3 transcription factor as an inhibitor of inflammatory responses and IFN-I induction in UTUC, which hindered CD8+ T-cell infiltration and activation. Our data suggest that the tested combination of chemotherapy with ATF3 suppression/IFN-I may improve UTUC immunogenicity and therapeutic response.
Fichier principal
Vignette du fichier
Clinical Translational Med - 2024 - Fauvre - STING‐ATF3 type I interferon crosstalk A potential target to improve.pdf (1.72 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
licence

Dates et versions

hal-04740088 , version 1 (24-01-2025)

Licence

Identifiants

Citer

Alexandra Fauvre, Margot Machu, Audrey Merienne, Nadia Vezzio-Vie, Thomas Bessede, et al.. STING‐ATF3/type I interferon crosstalk: A potential target to improve anti‐tumour immunity in chemotherapy‐treated urothelial carcinoma. Clinical and Translational Medicine, 2024, 14 (9), pp.e70011. ⟨10.1002/ctm2.70011⟩. ⟨hal-04740088⟩
39 Consultations
0 Téléchargements

Altmetric

Partager

More